Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology
Files
Publication date
2006
Authors
Temming, K.
Lacombe, M.
van der Hoeven, P.
Pradash, J.
Gonzalo, T.
Dijkers, E.C.F.
Orfi, L.
Keri, G.
Poelstra, K.
Molema, G.
Editors
Advisors
Supervisors
DOI
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Keywords
Medical technology, Farmacie(FARM), Biomedische technologie en medicijnen, Pharmacology
Citation
Temming, K, Lacombe, M, van der Hoeven, P, Pradash, J, Gonzalo, T, Dijkers, E C F, Orfi, L, Keri, G, Poelstra, K, Molema, G & Kok, R J 2006, 'Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology', Bioconjugate Chemistry, vol. 17, pp. 1246-1255.